Custom Oligonucleotide Synthesis Service
Overview
Oligonucleotides are usually composed of up to 20 short-chain nucleotides (deoxyribonucleotides or ribonucleotides). They have a variety of primer lengths. It can be used in pre-designed, customized, or randomized forms for applications in microarrays, gel migration analysis, artificial gene synthesis forensic medicine, etc. There are many types of current research, such as tiny ribonucleic acids, small interfering ribonucleic acids, nucleic acid aptamers, etc. They can achieve very high selectivity by pairing with DNA, mRNA, or pre-mRNA. Based on this, oligonucleotide has a variety of uses. It can be used in diagnostic tests, antisense agents in target validation, competitive inhibitors of transcription factors, and so on. It can also be used as a stimulator of the immune system or as a biotherapeutic agent for the treatment of diseases. In addition, it can precisely inhibit certain genes, silencing genes that code for abnormalities, thus preventing the expression of many faulty proteins.
Key Technologies
At CD BioGlyco, our key technologies for custom oligonucleotide synthesis center on advanced chemical synthesis using optimized stepwise nucleotide addition protocols and enzymatic synthesis for efficient fragment assembly, complemented by four specialized purification methods (OPC columns, HPLC, desalting, PAGE) to ensure high-purity natural or modified oligonucleotides. We achieve precision through real-time reaction monitoring and enzymatic fragment joining.
Your Sequence, Our Science: Custom Oligos Perfected.
CD BioGlyco has excellent synthetic capabilities to meet a variety of custom synthesis needs. Synthetic oligonucleotides avoid the disadvantages of the natural. Due to some shortcomings of the traditional solid-phase methods, such as limited length and purity, scientists began to look for new synthesis methods. At present, we mainly use two methods of chemical synthesis and biological enzyme synthesis to produce.
Fig.1 Oligonucleotide R&D services. (CD BioGlyco)
- Oligonucleotide Synthesis Services
Oligonucleotides are usually prepared by: stepwise addition of nucleotide residues to produce a particular sequence. We synthesize various products using both chemical and biological methods. With advanced synthesis technology and laboratory equipment, we are capable of providing products of various specifications. We produce not only unmodified, standard products but also complex and various modified products based on our Oligonucleotide Modification Service.
Our primary method for oligonucleotide synthesis is solid-phase chemistry using phosphoramidites. This highly successful approach allows for the sequential addition of nucleotides to a growing chain anchored to a solid support, such as a CPG bead. The solid-phase method is highly efficient, scalable, and forms the basis for our high-throughput manufacturing.
For certain specialized applications requiring specific modifications or synthesis scales, we also offer liquid-phase synthesis, a method that can be advantageous for producing specific types of complex oligonucleotides.
We are at the forefront of exploring new technologies. While chemical synthesis is our current standard, we are actively developing and optimizing enzymatic synthesis methods, which are gaining traction as a greener and potentially more efficient alternative for certain applications.
We provide a tiered range of purification options to ensure the final product meets the specific purity requirements of your application.
This is the standard purification method, sufficient for most applications like standard PCR. It removes small molecule contaminants such as organic salts generated during the synthesis and deprotection processes.
This is a step up from desalination, providing a higher level of purity. It is ideal for applications that require a cleaner product than what desalting provides but do not demand the precision of HPLC or PAGE.
HPLC is the method of choice for purifying oligonucleotides that are modified with non-standard bases, fluorescent dyes, or linkers. Depending on the modification, we offer both reverse-phase and ion-exchange HPLC to separate the full-length product from truncated species based on differences in solvent affinity or charge.
PAGE is the most efficient method for isolating full-length, unmodified oligonucleotides from shorter failure sequences. This method is particularly useful for longer oligonucleotides intended for applications like cloning, where a high level of purity is critical.
Workflow
Publication Data
DOI.: 10.1038/s42004-024-01216-0
Journal: Communications Chemistry
Published: 2024
Results: This perspective reviews controlled enzymatic synthesis (CES) as an emerging method for producing oligonucleotides, contrasting it with traditional chemical synthesis. The authors highlight how CES uses template-independent polymerases (like terminal deoxynucleotidyl transferase) to iteratively add nucleotides to a primer immobilized on a solid support. Crucially, each nucleotide is temporarily blocked (e.g., at the 3'-OH position) to ensure single-base additions per cycle, followed by deblocking. The review details advancements in designing reversible blocking groups and engineered polymerases for efficient DNA synthesis. It also examines significant challenges for extending CES to RNA and xenonucleic acids due to polymerase compatibility and suitable blocking strategies. The authors conclude by suggesting that combining CES with ligase-based assembly could overcome current length limitations and enable the production of complex, modified oligonucleotides.
Applications of Custom Oligonucleotide Synthesis
- Plant chromosomes can be studied using the developed oligonucleotide probes. The study of plant chromosomes can ultimately provide a cytological basis for elucidating plant classification, origin, evolution, phylogeny, genetics, and so on.
- The occurrence of cancer is closely related to the abnormal regulation of signaling pathways, etc. Antisense oligonucleotide molecules are used to study the effects of cancer growth, metastasis, etc., in vitro and in vivo.
- Oligonucleotide primers can be used for gene cloning, sequencing, etc. Through its inhibition or silencing of gene expression enables screening for genetic diseases or identification of specific pathogens.
Advantages of Us
- We have excellent chemical and enzymatic synthesis capabilities. We monitor chemical reactions in real time to ensure optimal product quality.
- Enzymatic methods offer several advantages. Enzymatic reactions allow small fragments to be joined to become large fragments, thus speeding up the synthesis process.
- Oligonucleotides have a wide variety of biological applications, etc. Both natural and modified oligonucleotide products can be synthesized.
Frequently Asked Questions
Associated Services
Our oligonucleotide synthesis is complemented by related associated services for specific modifications:
- Affinity-plus Base Modification
- Inosine Modification
- 2'-O-methoxy-ethyl Bases (2'-MOE) Modification
- 2'-O-Methyl RNA Bases Modification
- Fluoro Bases Modification
CD BioGlyco aims to facilitate drug research, molecular probe assay development, and so on. We also provide production services such as Polynucleotide and Nucleoside-based Production. To learn more about our products and how to synthesize them, please feel free to contact us.
Reference
- Pichon, M.; Hollenstein, M. Controlled enzymatic synthesis of oligonucleotides. Communications Chemistry. 2024, 7(1): 138. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




